Kornimate/medical-research-clean huggingface dataset:
rett syndrome registry

Conditions: Rett Syndrome; Rett Syndrome, Atypical; Genetic Disease; Genetic Diseases, X-Linked; Intellectual Disability; Neurobehavioral Manifestations; Neurologic Manifestations; Neurologic Disorder; Neurodevelopmental Disorders; Nervous System Diseases

Summary: the rett syndrome registry is a longitudinal observational study of individuals with mecp2 mutations and a diagnosis of rett syndrome. designed together with the irsf rett syndrome center of excellence network medical directors, this study collects data on the signs and symptoms of rett syndrome as reported by the rett syndrome experts and by the caregivers of individuals with rett syndrome. this study will be used to develop consensus based guidelines for the care of your loved ones with rett syndrome and to facilitate the development of better clinical trials and other aspects of the drug development path for rett syndrome.


Eligibility criteria:
inclusion criteria: * male or female with a pathologic loss of function alteration of mecp2 exclusion criteria: * male or female with a gain of function alteration of mecp2, including those with mepc2 duplication or triplication

Keywords: rett syndrome mecp2 neurodevelopmental disorder registry natural history study
efficacy of noninvasive radiofrequency in attenuating diabetic neuropathic pain

Conditions: Diabetic Neuropathy, Painful

Summary: peripheral neuropathy increases the prevalence of diabetic foot ulcers following a decrease in foot sensation. therefore, the treatment of this disorder is very important.

the current study aimed to investigate the efficacy of tecar therapy on lower limb perfusion index (pi) and to evaluate the efficacy of tecar therapy in improving the peripheral vascularity, reducing foot pain, and improving the tactile sensation of the soles in diabetic peripheral neuropathy (dpn) patients. twenty three diabetic neuropathy patients were included in the study and underwent 12 sessions of capacitive tecar therapy over one month. pain, tactile sensation of the sole and pi were evaluated at the start and after each session till the end of the study.

Eligibility criteria:
inclusion criteria: * age 40-70 years * type ii dm with dpn (grade i-ii) in lower limbs * duration of dm\>5 years * visual analog scale (vas) ≥3 in the feet * sensory impairments in the lower extremities exclusion criteria: * patient with previous stenting or surgical intervention of lower limb arterial system. * patients with previous history of dvt. * pregnancy * diabetic infectious wound * cardiac pacemaker presence * severe liver and kidney dysfunction or history of heart and lung disease.
testing an herbal pain relief patch to reduce pain in cancer survivors

Conditions: Cancer; Remission

Summary: the purpose of this study is to find out whether tibetree pain relieving plaster, an herbal pain relief patch, may be able to reduce this pain. tibetree pain relieving plaster is available as an over-the-counter (non-prescription) treatment for the temporary relief of minor aches and pains in muscles and joints. this study is the first to test this treatment in people who have had cancer.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years or older * a diagnosis of cancer with no restrictions placed on type of cancer or stage. eligibility criteria will not be restricted to msk confirmed biopsy/diagnosis. participating institution's testing is sufficient for other study sites * completed active treatment (surgery, chemotherapy, and/or radiotherapy) at least one month prior to study initiation (patients on continued hormone treatment or maintenance targeted therapies will not be excluded). * patients currently have no evidence of disease * ambulatory (karnofsky functional score of ≥ 60) * having a focused location of regional musculoskeletal pain (e.g. joints, extremities, back, neck) that can be covered by one patch of prp * worst pain score (numeric pain rating scale) 5 or above in the preceding week * pain for at least 3 months and at least 15 days with pain in the preceding 30 days; and willingness to adhere to and understanding of all study-related procedures, including randomization to one of the two possible choices * able to understand informed consent and provide signed informed consent form exclusion criteria: * patients with non-musculoskeletal pain syndromes (headache, facial pain, chest pain, visceral abdominal pain) will be excluded if these are the sole source of pain but can be present as co-morbid conditions as long as a patient has a primary musculoskeletal pain condition defined as above. * patients have generalized musculoskeletal pain such as fibromyalgia * use of corticosteroid drugs by any route of administration within 30 days * patients with significant self-reported skin disorders * patients with open wounds, infections, skin trauma at skin overlying area of pain * patients with documented history of skin sensitivity to adhesive or allergic reaction to other patches or topical analgesics * patients with documented skin allergic reaction to plants or herbs * patients who are in active treatment (chemotherapy, surgery, radiotherapy) * plan to change or initiate other pain medications or interventions (e.g. physical therapy, acupuncture, injection). patients may remain on their current pain regimen.

Keywords: tibetree tibetree pain-relieving cancer pain cancer survivor 20-496 memorial sloan kettering cancer center
effect of prebiotic fos on intestinal abundance of faecalibacterium prausnitzii in patients with crohn´s disease

Conditions: Crohn Disease

Summary: fos improve gut colonization by faecalibacterium prausnitzii in patients with crohn's disease

to demonstrate that fos increases counts of faecalibacterium prausnitzii in faecal samples from crohn's disease patients

Eligibility criteria:
inclusion criteria: * patients between 18 and 65 years old * crohn's disease patients * inflammatory activity confirmed by imaging techniques (colonoscopy or magnetic resonance imaging (mri)) * refractory inflammatory luminal disease (with or without perianal involvement) at any level of the gastrointestinal tract requiring therapy with adalimumab,according to standard clinical practice. * stable maintenance of any other medication (corticosteroids and / or immunosuppressants and/or 5-aminosalicylic acid (5-asa)) for the past 4 weeks * screening tests required for a safe administration of anti tumour necrosis factor (anti-tnf) antibodies will be performed according to standard clinical practice exclusion criteria: * subjects consuming prebiotic supplements (inulin, fos, galactooligosaccharides (gos)) in their regular diet. * antibiotic use within the past 2 months * previous anti-tnf therapy.
clinical condition and sleep quality factors associated with sleep bruxism in adults.

Conditions: Sleep Bruxism, Adult

Summary: this cross-sectional study will evaluate the association between sociodemographic, occupational, clinical conditions, psychological (sense of coherence), sleep quality variables and sb diagnosed by psg, the gold standard exam with audio-visual resources obtained at pelotas sleep institute.

sleep bruxism is defined as a masticatory muscle activity during sleep that is characterised as rhythmic (phasic) or non-rhythmic (tonic) and should be considered a risk factor rather than a disorder in otherwise healthy individuals. the diagnosis of sleep bruxism often is challenging and despite the use of questionnaires, clinical exams and portable devices, based on current knowledge, the polysomnography with audio-video recordings emerges as the gold-standard criteria for a definite sleep bruxism diagnosis. included on the questionnaire there is a registration form, which contains: included: age at time of data collection , gender, marital status , and education level ; occupational: individuals were asked about work outside home, and working hours; clinical condition: body mass index, smoking; alcohol consumption; use of sleeping pills; respiratory allergy and psychological: sense of coherence .

Eligibility criteria:
inclusion criteria: * all adults (aged 20 to 60 years) and elderly (aged \>60 years) exclusion criteria: * inadequate cognitive capacity to understand and answer the questionnaires; * degraded psg image quality; * questionnaires filled incorrectly; * participants who presented a history of epilepsy that could interfere in the results of polysomnography.

Keywords: grind polysomnography rhythmic masticatory muscle activity sleep bruxism
cognitive effects of atomoxetine in humans: genetic moderators

Conditions: Addiction

Summary: the overall goal of this study is to determine if atomoxetine treatment improves selective cognitive functions in abstinent cocaine users, compared to healthy controls. the study will also test if a functional variation of the net promoter polymorphic region (netppr) moderates the cognitive effects of atomoxetine.

this will be a double-blind, placebo-controlled, crossover study, with cocaine use (cocaine users vs. healthy controls) and net aagg4 status (l4/ l4 vs. l4/s4 or s4/ s4 genotype) as the between-subject factors. similar to previous studies, we propose to compare individuals with two copies of the l4 allele to participants with at least one s4 allele because only less than two percent of the general population is homozygous for the s4 allele. forty cocaine users and 40 healthy controls will participate in 3 test sessions, where they will be assigned to 40 mg atomoxetine, 80 mg atomoxetine, or placebo. outcome measures will include physiological, subjective, and cognitive performance measures. to date this study has 35 completers and currently in data analysis. (january 2016)

Eligibility criteria:
inclusion criteria: * male and females, between the ages of 21 and 50; * no current dependence or abuse of drugs of abuse or alcohol (except and tobacco); * no current medical problems and normal ecg; * for women, not pregnant as determined by pregnancy screening nor breast feeding, and using acceptable birth control methods. exclusion criteria: * current major psychiatric illnesses including mood, psychotic, or anxiety disorders; * history of major medical illnesses; including liver diseases, heart disease, or other medical conditions that the physician investigator deems contraindicated for the subject to be in the study; * known allergy to atomoxetine; * use of monoamine oxidase inhibitor within the last month (clinically atomoxetine administration is contraindicated with or within 2 weeks of discontinuation of monoamine oxidase inhibitor therapy).

Keywords: abstinent cocaine users cognitive testing
comparison of 2 vials of components of a synthetic geranium oil

Conditions: Neuropathic Pain

Summary: the purpose of this study is to determine which component of an artificial geranium oil helps to reduce your neuropathy pain.

ept 101 is a double-blind successive crossover study designed to determine which components of a synthetic geranium oil provide analgesic relief, with the objective of identifying and purifying the active substance. this is not a hypothesis-generating trial, nor is it confirming a hypothesis. the trial uses human volunteers in an efficacy-directed decomposition of a complex mixture. patients with a diagnosis of neuralgia or neuropathy who respond to geranium oil will test two vials of components of a synthetic geranium oil for application to the maximally painful area in succession. they will treat their condition in the clinic and fill out a patient diary on separate days. the primary objective is the patient opinion of which vial has greatest analgesic efficacy. efficacy will be measured primarily by reduction in pain intensity summed over the first two hours, compared with the pain intensity during the 30 minutes preceding application. following the comparison of the first two vials, the vial judged efficacious will be decomposed into two further vials and the patients will repeat the evaluation described above. at least eight pair-wise comparisons will be required to determine and confirm which of the 100+ ingredients of a synthetic geranium oil are analgesic, provided there is only one such ingredient.

Eligibility criteria:
inclusion criteria: * you are eligible to participate in this study if you have completed the study ept 100 and geranium oil relieves your neuropathy pain successfully. exclusion criteria: * you are ineligible to participate in this study if you have completed the study ept 100 and geranium oil does not relieve your neuropathy pain successfully

Keywords: geranium oil neuropathy shingles herpes zoster
oral health-related quality of life of early childhood caries using silver diamine fluoride versus drill and fill technique

Conditions: Oral Health Related Quality of Life; Early Childhood Caries

Summary: the clinical trial aims to compare children's oral health-related quality of life (ohrql) following caries arrest technique using sdf versus conventional drill and fill in the children with ecc

early childhood caries (ecc) has been an increasing issue in many countries and has become a significant health problem, especially in socially disadvantaged populations. ecc is a specific form of caries that occurs in children with primary teeth. ecc is characterized as "the early onset of caries in young children with often fast progression which can finally result in complete destruction of the primary dentition". management of cavitated carious lesions in primary teeth in very young children is time-consuming due to their lack of cooperation, so one of the alternative procedures could be performed with silver diamine fluoride (sdf), to its effectiveness in arresting the activity of carious lesions (cavitated and non-cavitated). it is easy to apply even outside dental offices, and relatively inexpensive solutions can be used particularly when compared to restorative intervention.

Eligibility criteria:
inclusion criteria: * children aged 3 to 5 years, in good general health and medically within normal. * the parents provided written informed consent. * carious vital primary molars with reversible pulpitis. * restorable teeth. * normal radiographic findings. exclusion criteria: * unable to attend follow-up visits. * refusal of participation. * previously accessed teeth.
l-tyrosine supplementation in patients with fibromyalgia

Conditions: Fibromyalgia

Summary: patients in the study, who have a diagnosis of fibromyalgia, will be randomly assigned to take the amino acid l-tyrosine or placebo (blank pill) for 3 weeks. they will fill out questionnaires about their symptoms and see if they have any improvement. the investigators hypothesis is that taking tyrosine will help alleviate the symptoms of fibromyalgia.

fibromyalgia is a chronic pain syndrome with few treatment options available. the amino-acid l-tyrosine is the precursor for norepinephrine in the central nervous system (cns). norepinephrine in the cns has important roles in pain and mood modulation and descending inhibition of pain pathways. by giving the precursor l-tyrosine in high doses we believe that we can increase levels of norepinephrine in the cns. to study this question we designed a randomized blinded pilot study of 30 patients. patients are randomly assigned to one of 3 groups (placebo, tyrosine 1000mg/day, and tyrosine 2000mg/day.) for 3 weeks. patients then complete the brief pain inventory (bpi) daily and the fibromyalgia impact questionnaire (fiq) on day 1 and day 21. patients also complete a drug diary. they are monitored weekly for progress during the study.

Eligibility criteria:
inclusion criteria: * diagnosis of fibromyalgia * pain greater than 4/10 * age greater than 18 exclusion criteria: * pregnant * age less than 18

Keywords: diet fibromyalgia pain drug amino-acid fatigue
the relationship of anesthesia method with serum lactate level in craniotomies

Conditions: Intracranial Neoplasm; Hyperlactatemia; Brain Tumor; Hypoperfusion

Summary: the investigators aimed to research the incidence of hyperlactatemia in craniotomy cases, the relationship of lactate elevation with tumor type and other factors that may be related, and whether the general anesthesia method applied (inhalation anesthesia or total ıntravenous anesthesia) affects lactate level.

lactate level is one of the easy-to-measure parameters that are frequently used in anesthesia and intensive care clinical practice, especially to evaluate the severity of disease and the response to treatment. in patients with high lactate levels, the first considerations are hypoperfusion and sepsis. however, many causes such as trauma, seizures, ischemia, diabetic ketoacidosis, thiamine deficiency, malignancies, liver dysfunction, genetic disorders, toxins, drugs, etc. can be associated with increased lactate. many tissues in the body can produce lactate. 25% of production is from muscle, 25% skin, 20% brain, 20% rbc and 10% bowel cells. some malignancies, especially hematological cancers, have also been associated with increased lactate. in recent years, it has been reported that serum lactate levels are associated with the degree of glial tumor malignancy, and that lactate can even be used as a non-invasive malignancy biomarker in brain tumors. in a recent study, it was reported that the type of 'glioblastoma multiforme' among patients who underwent craniotomy with the diagnosis of intracranial brain tumor was an independent influencer factor for preoperative and postoperative hyperlactatemia. anesthesia is one of the factors that can affect lactate levels due to its effect on systemic perfusion and the hepatic effects of anesthetic drugs. it looks like that there is no study in the literature on the effect of anesthesia technique on hyperlactatemia in patients who underwent craniotomy. therefore the investigators aimed to research the incidence of hyperlactatemia in craniotomy cases, the relationship of lactate elevation with tumor type and other factors that may be related, and whether the general anesthesia method applied (inhalation anesthesia or total ıntravenous anesthesia) affects lactate level.

Eligibility criteria:
inclusion criteria: * scheduled to undergo elective craniotomy for an intracranial mass * adult patients exclusion criteria: * emergency * in situations that may cause hyperlactatemia (such as sepsis, hepatic or renal failure, shock state, or patients who need inotropic support)

Keywords: hyperlactatemia craniotomy total intravenous anesthesia general anesthesia
feasibility and tolerance study for the treatment of varicose ulcers by cyanoacrylate glue (etuvve)

Conditions: Venous Leg Ulcer

Summary: ulcers of the lower limbs are a major public health problem whose management needs to be further improved, particularly in terms of healing time, prevalence and recurrence rate. ulcers of venous origin, or mixed arteriovenous and predominantly venous, represent the majority of leg ulcers with an estimated proportion of 70 to 80% of cases. these are painful, disabling conditions that are difficult to treat in a lasting way. this study focuses on a treatment strategy with endovascular glue. the advantage of treating ulcers with cyanoacrylate glue is the possibility of occluding the great saphenous vein over its entire length, freeing itself from neurological complications secondary to endovenous thermal techniques (laser, radiofrequency), as well as the possibility of treating by direct puncture any perforators or tributaries feeding the ulcer. this treatment strategy would improve the healing process for a lasting resolution of this pathology. this study aims to describe the feasibility and tolerance of this type of treatment in the resolution of varicose ulcers.


Eligibility criteria:
inclusion criteria: * primary insufficiency of the great saphenous vein (gvs) by a reflux\> 0.5 second from the inter-fascial saphenous trunk to the upper 1/3 of the thigh extending over the entire height of the thigh either in the saphenous compartment or in at least one extra-fascial tributary, in a standing patient, by compression of the calf * ceap: c6, ulcer present on a single leg whose size can be captured by a simple photograph * diameter of the gvs at the saphenofemoral junction ≥3 or ≤12 millimeters * patient affiliated or beneficiary of a social security scheme * patient having signed the informed consent exclusion criteria: * patient with a circumferential ulcer * patient with ipsilateral small saphenous vein insufficiency * presenting a serious current pathology and / or a life expectancy of less than 5 years * history of deep or superficial vein thrombosis in the previous 6 months * patient with arteriopathy obliterating of the affected lower limb, with an ips \ 1.3 * with post-thrombotic obstructive syndrome in the popliteal and / or femoral and / or iliac stage on the ipsilateral lower limb * presenting primary or post-thrombotic axial deep venous reflux on the ipsilateral lower limb * suspicion of non-post-thrombotic iliac compression on doppler ultrasound * contraindication to the intended treatment technique * known allergy to cyanoacrylate glue or xylocaine * patient with a bmi greater than 40 (morbid obesity) * patient whose geographical distance is not compatible with the follow-up of the study * pregnant or breastfeeding woman * patient participating in another clinical study * patient linguistically or psychically unable to understand the information given, to give informed consent or to answer the study questionnaires. * protected patients: adults under some guardianship or other legal protection; hospitalized without consent

Keywords: endovenous treatment glue
anxiety and depression among pregnant women during covid-19 pandemic

Conditions: Covid19

Summary: pregnancy and early parenthood are life changing periods characterized by intense emotions and a high vulnerability to emotional problems. overall 10 - 20 % of pregnant women and women in early postpartum period suffer from mental health problems. in the first months of 2020 , pregnant and breastfeeding women have also needed to face the covid19 pandemic including the exceptional quarantine measures that have disturbed private and professional life . in addition to the fear of infection , these measures might have negatively impacted the emotional wellbeing of women . as depressive symptoms and anxiety in the pre and peripartum period have been associated with adverse maternal , neonatal and infant outcomes , the psychological impact of covid19 , and its associated quarantine measures , on pregnant women and new mothers is cause for concern


Eligibility criteria:
inclusion criteria: all pregnant women presented to the antenatal care clinic, will be included in the study irrespective of the gestational age of the pregnancy exclusion criteria: women previously diagnosed with any psychiatric disorder.